HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jhanwar, Y. S. Articles by Straus, D. J. Search for Related Content PubMed PubMed Citation Articles by Jhanwar, Y. S. Articles by Straus, D. J.

The Role of PET in Lymphoma^*

¹ Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; and ² Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: David J. Straus, MD, Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: strausd{at}mskcc.org

Malignant lymphomas are a heterogeneous group of diseases whose treatment and prognosis depend on accurate staging and evaluation of histologic features. The conventional imaging procedure is CT; however, nuclear medicine imaging has also had a prominent role. Single-photon imaging with ⁶⁷Ga-citrate has been widely used for lymphomas. PET with ¹⁸F-FDG has gained a role in the staging and follow-up of lymphomas, largely replacing gallium as the nuclear medicine study of choice. ¹⁸F-FDG PET has proved useful in the staging and follow-up of Hodgkin's disease and non-Hodgkin's lymphoma (especially more aggressive types), and the widespread use of PET/CT has also increased the sensitivity and specificity. Its usefulness for the staging of slow-growing lymphomas has not been established. After the basics of staging and classification of lymphomas have been outlined, this article will review the role of ¹⁸F-FDG PET in the management of patients with lymphoma. PET tracers other than ¹⁸F-FDG, such as positron-emitting isotopes of gallium and the cellular proliferation marker ¹⁸F-3'-deoxy-3'-fluorothymidine, will be discussed and future directions for PET in lymphoma proposed.

Key Words: ⁶⁷Ga-citrate • Hodgkin's disease • lymphoma • PET

This article has been cited by other articles:

				H. Mocikova, P. Obrtlikova, B. Vackova, and M. Trneny Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study Ann. Onc., November 9, 2009; (2009) mdp522v1. [Abstract] [Full Text] [PDF]

				A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory Introduction Oncologist, October 1, 2009; 14(suppl_2): 1 - 3. [Full Text] [PDF]

				T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF]

				N. P. Leite, N. Kased, R. F. Hanna, M. A. Brown, J. M. Pereira, R. Cunha, and C. B. Sirlin Cross-sectional Imaging of Extranodal Involvement in Abdominopelvic Lymphoproliferative Malignancies RadioGraphics, November 1, 2007; 27(6): 1613 - 1634. [Abstract] [Full Text] [PDF]